TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
暂无分享，去创建一个
C. Tam | A. Schwarer | D. White | T. Hughes | J. Trotman | S. Branford | A. Herschtal | A. Grigg | D. Yeung | M. Hertzberg | C. Arthur | D. Ross | C. Forsyth | D. Hiwase | M. Osborn | Y. Kwan | J. Braley | R. Filshie | S. Issa | A. Mills | M. Kornhauser | J. Beresford | J. Taper | T. Hughes | D. White | Jodi A Braley